Silver Spring-based United Therapeutics’ quarterly sales got a boost from its newest treatment for pulmonary arterial hypertension, while higher research and development costs, and a bigger payroll, dragged down the bottom line.
United Therapeutics had second quarter revenue of $347.2 million, up 7.5 percent from $322.8 million in revenue in the same quarter a year earlier. Net income was $99.2 million, or $1.91 per share, compared to net income of $111.9 million, or $2.10 per share a year ago.
{iframe}http://www.bizjournals.com/washington/news/2015/07/28/united-therapeutics-gets-boost-from-new-drug.html?ana=e_du_pap&s=article_du&ed=2015-07-28&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1438115257{/iframe}